H.C. Wainwright Starts Windtree Therapeutics (WINT) at Neutral, 'Istaroxime Poised to Navigate Late-Stage Development'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to H.C. Wainwright Starts Windtree Therapeutics (WINT) at Neutral, 'Istaroxime Poised to Navigate Late-Stage Development'

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

January 2, 2024 4:05 PM EST

The new preclinical data further supports istaroxime clinical data from three Phase 2 studies

Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute heart failure

WARRINGTON, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (Windtree or the Company) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced new preclinical data on the Companys lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat... More